OCUL Ocular Therapeutix

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024:

UBS Virtual Opthalmology Day 2024

Fireside Chat Date: Wednesday, October 2, 2024

Presentation Time: 3:00 PM ET

Ocular Presenter: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer

Location: Virtual

In addition to the fireside chat, Ocular leadership will host investor meetings at the conference. A live webcast of the fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations



EN
25/09/2024

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registra...

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for ...

October 15, 2024 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule...

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards were made as inducements material to Mr. Anderman’s acceptance of employment with O...

October 9, 2024 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix™ to Present at October Ophthalmology Meetings BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024. Presentation & Panel Details (all times CT): Eyecelerator® @ AAO 2024: October 17 ...

October 9, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 45.98
SHAK Shake Shack In...
PLAY Dave & Buster's... ... (+65)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SHAK SHAKE SHACK INC. CLASS A
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OCUL OCULAR THERAPEUTIX
HNRG HALLADOR ENERGY CO.
EAT BRINKER INTERNATIONAL INC.
DECK DECKERS OUTDOOR CORPORATION
CSIQ CANADIAN SOLAR INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
CALM CAL-MAINE FOODS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BBW BUILD-A-BEAR WORKSHOP
ASPN ASPEN AEROGELS
APOG APOGEE ENTERPRISES INC.
AMSC AMERICAN SUPERCONDUCTOR CORP.
ALB ALBEMARLE CORPORATION
AAOI APPLIED OPTOELECTRONICS INC.
COF CAPITAL ONE FINANCIAL CORPORATION
ZUMZ ZUMIEZ INC.
VFC V.F. CORPORATION
CRVS CORVUS PHARMACEUTICALS
DESP DESPEGAR.COM CORP.
FNKO FUNKO CLASS A
AMD ADVANCED MICRO DEVICES INC.
ACMR ACM RESEARCH
PPIH PERMA PIPE INTERNATIONAL HOLDINGS
GLOB GAZIT-GLOBE LTD.
PLMR PALOMAR HOLDINGS
CAPR CAPRICOR THERAPEUTICS
CRMD CORMEDIX INC.
BILL BILL.COM HOLDINGS
ADPT ADAPTIVE BIOTECHNOLOGIES
GII SPDR S&P GLOBAL INFRASTRUCTURE
TVTX TRAVERE THERAPEUTICS INC
VHI VALHI INC.
ALKT ALKAMI TECHNOLOGY INC
SOFI SOFI TECHNOLOGIES INC
EVGO EVGO INC
ENVX ENOVIX CORP
TSE TRINSEO PLC
ASTS AST SPACEMOBILE INC
PLL PIEDMONT LITHIUM INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
RDW REDWIRE CORP
COYA COYA THERAPEUTICS INC
SKWD SKYWARD SPECIALTY INS GROUP INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
WGS GENEDX HOLDINGS CORP.
KGS KODIAK GAS SERVICES INC
BYRN BYRNA TECHNOLOGIES INC
NMRA NEUMORA THERAPEUTICS INC
ATGL ALPHA TECHNOLOGY GROUP LTD
NGNE NEUROGENE INC
DAVE DAVE INC
LENZ LENZ THERAPEUTICS INC
IBTA IBOTTA INC
FIP FTAI INFRASTRUCTURE INC
CLMT CALUMET INC
NUTX NUTEX HEALTH INC
DOGZ DOGNESS INTERNATIONAL CORP
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
TBNK TD CANADIAN BANK DIVIDEND INDEX ETF
RDDT REDDIT INC
10/08/24 October 8, 2024 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 202...

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024 BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024: UBS Virtual Opthalmology Day 2024Fireside Chat Date: Wednesday, October 2, 2024Presentation Time: 3:00 PM ETOcular Pres...

September 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch